BSX Stock Recent News

Here is how Boston Scientific (BSX) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Boston Scientific is a 'forever stock' due to management foresight, robust R&D, and leadership in AI-driven medical devices. Despite a weak valuation grade, its strong financials, global expansion, and AI integration justify a long-term buy rating. Key risks include regulatory changes, insider selling, and potential revenue impacts from federal healthcare cutbacks; buy on dips is advised.

We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divestiture of non-core assets, new leadership, and a focus on high-growth hospital monitoring technologies. Eli Lilly remains a core holding due to its leadership in diabetes and obesity treatments, robust pipeline, and potential to triple revenues by 2030.

Zacks.com users have recently been watching Boston Scientific (BSX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

LONDON & BOSTON--(BUSINESS WIRE)--Keyron appoints former FDA and Boston Scientific leaders as ForePass—a breakthrough device for severe metabolic disease—prepares for clinical trials.

Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and Boston Scientific (BSX). But which of these two stocks is more attractive to value investors?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

PEMBROKE, Bermuda--(BUSINESS WIRE)--Gold Reserve Ltd. (TSX.V: GRZ) (BSX: GRZ.BH) (OTCQX: GDRZF) (“Gold Reserve” or the “Company”) announces the secondary listing on the Bermuda Stock Exchange (the “BSX”) of 122,714,914 Common Shares of Gold Reserve Ltd. effective today. Trading on the BSX will commence on August 4, 2025 under the ticker (BSX: GRZ.BH). The Company's primary listing is on the TSX Venture Exchange (TSX.V: GRZ) and the Company also continues to trade over the counter (OTCQX: GDRZF).

Boston Scientific (BSX -0.17%), a leading medical device maker known for its heart and surgical products, released second-quarter results on July 23, 2025. Revenue reached $5.06 billion for Q2 2025, beating analyst estimates of $4.89 billion.